All > Chronic Kidney Disease > High Blood Pressure

CIN-107 for Kidney Diseases

Phase-Based Progress Estimates

Effectiveness

Safety

CinCor Site 42, Los Angeles, CA

Kidney Diseases+4 More

CIN-107 - Drug

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18+

All Sexes

What conditions do you have?

Select

Eligibility

18+

All Sexes

What conditions do you have?

Select

Study Summary

This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension and Chronic Kidney Disease (CKD).

Eligible Conditions

Kidney Diseases
Hypertensive disease
Chronic Kidney Disease (CKD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Kidney Diseases

BI 764198

CIN-107

Finerenone (Kerendia, BAY94-8862)

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: At Week 26

At Week 26

Change from baseline in SBP

Change from baseline in diastolic blood pressure (DBP)

Change from baseline in estimated glomerular filtration rate (eGFR)

Change from baseline in mean seated systolic blood pressure (SBP)

Change from baseline in urinary albumin-to-creatinine ratio (UACR)

Percentage of patients achieving SBP <130mmHg

Trial Safety

Safety Progress

2 of 3

This is further along than 68% of similar trials

Other trials for Kidney Diseases

BI 764198

CIN-107

Finerenone (Kerendia, BAY94-8862)

Trial Design

3 Treatment Groups

Low dose CIN-107

1 of 3

High dose CIN-107

1 of 3

Placebo

1 of 3

Experimental Treatment

Non-Treatment Group

300 Total Participants · 3 Treatment Groups

Primary Treatment: CIN-107 · Has Placebo Group · Phase 2

Low dose CIN-107

Drug

Experimental Group · 1 Intervention: CIN-107 · Intervention Types: Drug

High dose CIN-107

Drug

Experimental Group · 1 Intervention: CIN-107 · Intervention Types: Drug

Placebo

Drug

PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CIN-107

2019

Completed Phase 2

~470

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: at week 26

Closest Location: CinCor Site 42 · Los Angeles, CA

2022First Recorded Clinical Trial

1 TrialsResearching Kidney Diseases

2 CompletedClinical Trials

Who is running the clinical trial?

ParexelIndustry Sponsor

265 Previous Clinical Trials

94,654 Total Patients Enrolled

9 Trials studying Kidney Diseases

759 Patients Enrolled for Kidney Diseases

CinCor Pharma, Inc.Lead Sponsor

7 Previous Clinical Trials

894 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

You are taking an ACEi or ARB at the maximum tolerated daily dose.

You have a mean seated SBP of 140 mmHg or more.

You have a prior diagnosis of mild-to-severe chronic kidney disease.

About The Reviewer

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References